SiSaf
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3 Huxley Rd, Guildford, Surrey, GU2 7RE,...Phone Number
+44 1483912002Website
www.sisaf.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About SiSaf
SiSaf Ltd is a biopharmaceutical company specializing in RNA therapeutics for cancer and musculoskeletal disorders. They utilize their proprietary Bio-Courier technology, which combines bioabsorbable silicon with organic materials, to enhance the delivery of nucleic acids. The company is focused on developing a pipeline of innovative treatments, including therapies for pancreatic cancer, metastatic cancer, and osteopetrosis. SiSaf is headquartered in Guildford, England, and operates state-of-the-art research and manufacturing facilities.Explore more
SiSaf Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SiSaf your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if SiSaf had a recent Job posting/layoffs
Earning: See what the market has to say on SiSaf recently announced quarterly report
SiSaf, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if SiSaf has recently received funding, and reach out quickly before it becomes old news!
Check out if SiSaf is spiking on competitors!
Product Launch: Get notified when SiSaf launches new products
Funding: Get notified immidiatlly once SiSaf has new funding data
Congratulate Masked Content for being promoted to Masked Content at SiSaf
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to SiSaf
Compare insights from companies similar to SiSaf, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SiSaf is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SiSaf is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SiSaf.
SiSaf financials insights
Gather financial insights about SiSaf, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$3.5M
2020
Series B
$13.2M
SiSaf Tech Stack
A closer look at the technologies used by SiSaf
See more technologies
SiSaf News & Media
FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis
GUILDFORD, England, May 15, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant Osteopetrosis Type 2 (ADO2), has been granted Orphan Drug Designation by the U.S. FDA. In addition, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for the treatment of Autosomal Dominant Osteopetrosis.SiSaf Appoints Dr. Richard Goodfellow to Board of Directors
GUILDFORD, England, April 05, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announced that it has appointed Dr. Richard Goodfellow to its Board of Directors. Richard draws on four decades of international experience across the biotechnology and pharmaceutical sectors, including leadership roles in business development and Chief Executive of Scancell, an AIM listed clinical stage immuno-oncology biopharmaceutical company. He has acted as a consultant to SiSaf sincSiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
GUILDFORD, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announces its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer. The collaboration will combine SiSaf’s expertise in RNA delivery using its Bio-Courier silicon-stabilized hybrid lipid nanoparticles (sshLNPs) and the University of Leipzig’s expeSiSaf's Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation
GUILDFORD, England , Oct. 12, 2022 /PRNewswire/ -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that it is initiating the U.S. FDA Regulatory process to obtain an Orphan Drug Designation for SIS-101-ADO, a siRNA therapeutic for patients with Autosomal Dominant...
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding SiSaf
Sign Up For FreeTo access detailed company insights
SiSaf Ltd is a biopharmaceutical company specializing in RNA therapeutics for cancer and musculoskeletal disorders. They utilize their proprietary Bio-Courier technology, which combines bioabsorbable silicon with organic materials, to enhance the delivery of nucleic acids. The company is focused on developing a pipeline of innovative treatments, in... Read More
